Article (Scientific journals)
Analytical and clinical validation of the new Abbot Architect 25(OH)D assay: fit for purpose?
Cavalier, Etienne; LUKAS, Pierre; BEKAERT, Anne-Catherine et al.
2017In Clinical Chemistry and Laboratory Medicine, 55 (3), p. 378-384
Peer Reviewed verified by ORBi
 

Files


Full Text
Analytical and clinical validation of the new Abbot Architect 25 OH D assay - fit for purpose.pdf
Publisher postprint (1.37 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
assay performance; concordance; immunoassay; LC-MS/MS; supplementation; vitamin D; Vitamin D2; Vitamin D3
Abstract :
[en] BACKGROUND: We provide a clinical and analytical evaluation of the reformulated version of the Abbott Architect 25-hydroxyvitamin D assay. We compared this assay with three commercial automated immunoassays and against a VDSP-traceable liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in six different populations. We also supplemented 40 healthy volunteers with either 600,000 IU of vitamin D2 or 100,000 of vitamin D3 to evaluate the performance of the immunoassays vs. the LC-MS/MS. METHODS: Precision and limit of quantification were assessed, 25(OH)D2 and C3-epimer recovery were calculated. Two hundred and forty samples obtained in healthy Caucasians and Africans, osteoporotic, hemodialyzed and intensive care patients and 3rd trimester pregnant women were analyzed by all methods. Correlation was studied using Passing-Bablok and Bland-Altman analysis. Concordance correlation coefficient (CCC) was calculated to evaluate agreement between immunoassays and LC-MS/MS. We verified if patients were homogeneously classified with the immunoassays when they took vitamin D2 or vitamin D3 after 1, 7 and 28 days. RESULTS: We observed excellent analytical features and showed a very good correlation to the LC-MS/MS results in the overall population. Compared to the other immunoassays, concordance of the new Abbott assay with the LC-MS/MS was at least similar, and often better in diseased populations. Althought the cross-reactivity with 25(OH)D2 was not of 100%, there was no significant difference in the classifications of the patients, either supplemented with D2 or D3 or after 7 or 28 days. CONCLUSIONS: This modified version of the Abbott Architect assay is clearly improved compared to the previous one and presents a better agreement with the LC-MS/MS.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Cavalier, Etienne  ;  Université de Liège > Département de pharmacie > Chimie médicale
LUKAS, Pierre  ;  Centre Hospitalier Universitaire de Liège - CHU > Service de chimie clinique
BEKAERT, Anne-Catherine ;  Centre Hospitalier Universitaire de Liège - CHU > Service de chimie clinique
CARLISI, Ignazia ;  Centre Hospitalier Universitaire de Liège - CHU > Service de chimie clinique
Le Goff, Caroline  ;  Université de Liège > Département de pharmacie > Chimie médicale
DELANAYE, Pierre  ;  Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie
Souberbielle, Jean-Claude
Language :
English
Title :
Analytical and clinical validation of the new Abbot Architect 25(OH)D assay: fit for purpose?
Publication date :
March 2017
Journal title :
Clinical Chemistry and Laboratory Medicine
ISSN :
1434-6621
eISSN :
1437-4331
Publisher :
Walter de Gruyter, Berlin, Germany
Volume :
55
Issue :
3
Pages :
378-384
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 26 January 2017

Statistics


Number of views
301 (44 by ULiège)
Number of downloads
561 (30 by ULiège)

Scopus citations®
 
20
Scopus citations®
without self-citations
15
OpenCitations
 
17

Bibliography


Similar publications



Contact ORBi